Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Virology

• Publication date

  2011-10-19

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/JVI.05066-11PMID 22013063PMCID PMC3255876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Production of glycoprotein-deleted rabies viruses for monosynaptic tracing and high-level gene expression in neurons

  2010cited by this paper
• Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41

  2010cited by this paper
• Origins of resistance to the HIVgp41 viral entry inhibitor T20.

  2010cited by this paper
• HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.

  2010cited by this paper
• I-TASSER: a unified platform for automated protein structure and function prediction

  2010cited by this paper
• In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*

  2010cited by this paper
• Decline in human T-cell lymphotropic virus-1 prevalence in urban areas of Bissau, Guinea-Bissau: exploring the association with HIV infections

  2009cited by this paper
• HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide

  2009cited by this paper
• Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains

  2009cited by this paper
• Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains as Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors*

  2008cited by this paper
• Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition

  2008cited by this paper
• Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants

  2008cited by this paper
• Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.

  2008cited by this paper
• Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*

  2008cited by this paper
• Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors

  2008cited by this paper
• Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

  2008cited by this paper
• HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains

  2007cited by this paper
• Potent D-peptide inhibitors of HIV-1 entry

  2007cited by this paper
• Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue

  2007influential reference
• Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain Is Critical for Six-helix Bundle Stability and Virus Entry*

  2007cited by this paper
• Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.

  2007influential reference
• Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility ofHuman Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors

  2007cited by this paper
• Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

  2005cited by this paper
• Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120*

  2005cited by this paper
• T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

  2005influential reference
• Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment

  2004influential reference
• N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion

  2004cited by this paper
• Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

  2004influential reference
• HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.

  2003cited by this paper
• The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.

  2003cited by this paper
• The entry of entry inhibitors: A fusion of science and medicine

  2003cited by this paper
• Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy

  2002cited by this paper
• Mechanisms of viral membrane fusion and its inhibition.

  2001cited by this paper
• Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion

  1999cited by this paper
• Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.

  1998cited by this paper
• HIV entry and its inhibition.

  1998cited by this paper
• Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41

  1998cited by this paper
• Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

  1998cited by this paper
• Core structure of gp41 from the HIV envelope glycoprotein.

  1997cited by this paper
• Atomic structure of the ectodomain from HIV-1 gp41

  1997cited by this paper
• A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein.

  1997cited by this paper
• A trimeric structural domain of the HIV-1 transmembrane glycoprotein

  1995cited by this paper
• Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

  1994cited by this paper
• Nested fullerene-like structures

  1993cited by this paper
• HIV-1 inhibition by a peptide

  1993cited by this paper

• ADS-J21 is a novel HIV-1 entry inhibitor targeting gp41

  2024cites this paper
• Frequency of Fusion Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients

  2024cites this paper
• The Membrane-Proximal Region of C–C Chemokine Receptor Type 5 Participates in the Infection of HIV-1

  2017cites this paper
• A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity

  2017cites this paper
• Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile

  2017cites this paper
• An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene

  2016cites this paper
• Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations

  2016cites this paper
• Enfuvirtide−PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties

  2016cites this paper
• Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

  2015cites this paper
• Integrated Analysis of Residue Coevolution and Protein Structures Capture Key Protein Sectors in HIV-1 Proteins

  2015cites this paper
• Receptor Binding Domain Based HIV Vaccines

  2015cites this paper
• Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene

  2015cites this paper
• Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein

  2014cites this paper
• ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.

  2014cites this paper
• T-20-Resistant Strains Fusion Inhibitor That Is Active against Electrostatically Constrained Peptide HIV-1 Resistance Mechanism to an

  2014cites this paper
• Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics

  2014cites this paper
• Functional Characterization of Two scFv-Fc Antibodies from an HIV Controller Selected on Soluble HIV-1 Env Complexes: A Neutralizing V3- and a Trimer-Specific gp41 Antibody

  2014cites this paper
• HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains

  2013cites this paper
• Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket

  2013cites this paper
• Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41.

  2013cites this paper
• HIV-1 Variants with Reduced Sensitivity to Sulfated Oligosaccharide Muparfostat Contain Mutations in the Envelope Glycoproteins gp120 and gp41

  2013cites this paper
• A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

  2012cites this paper
• Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors

  2012cites this paper
• HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.

  2012cites this paper
• Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32M*

  2012cites this paper